PrognosDx Health, Accium announce research agreement
PALO ALTO, Calif.óPrognosDx Health has announced the addition of Dr. Jeffrey L. Wolf to its scientific advisory board. Wolf, the director of the Multiple Myeloma Program in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center and a Clinical Professor of Medicine at the University of California, San Francisco, specializes in multiple myeloma and bone marrow transplantation as a cancer treatment. In addition, PrognosDx Health has entered into a collaboration with Accium BioSciences for the co-development and commercialization of a series of high-value predictive histone biomarker tests. PrognosDx plans to leverage Accium's capabilities, including Accium's accelerator mass spectrometry platform, to advance its epigenetic biomarkers to the clinic and for the support of cancer drug resistance, drug efficacy and toxicity studies.